Capricor Therapeutics, Inc. (CAPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.40+1.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CAPR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 0.0 | 22.3 | 25.2 | 2.6 | 0.2 | 0.3 | 1.0 | 1.7 | 2.7 | 4.0 | 5.5 | 4.8 | — | 0.2 | 1.4 |
| Total Revenues | — | — | 22.3 | 25.2 | 2.6 | 0.2 | 0.3 | 1.0 | 1.7 | 2.7 | 4.0 | 5.5 | 4.8 | — | 0.2 | 1.4 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 99.7 | 84.5 | 50.0 | 36.4 | 21.8 | 13.6 | 8.5 | 5.1 | 12.1 | 10.8 | 16.0 | 13.8 | 7.8 | 5.2 | 2.6 | 4.1 |
| Operating Income | (135.2) | (108.1) | (42.6) | (24.1) | (29.7) | (20.9) | (13.7) | (7.7) | (15.3) | (12.9) | (17.0) | (12.6) | (6.0) | (6.9) | (2.1) | (4.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 3.0 | — | — | — | — | — | — | 0.0 | 0.4 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | — |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (0.0) | — |
| Other Non-Operating Income / Expenses | 5.7 | 3.1 | 2.1 | 1.8 | 0.7 | 0.9 | 0.0 | 0.1 | 0.1 | 15.3 | (1.8) | (0.2) | (0.2) | (2.0) | 0.0 | 0.0 |
| EBT, Incl. Unusual Items | — | (105.0) | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | 0.0 | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | — |
| Net Income | ||||||||||||||||
| Net Income | (129.4) | (105.0) | (40.5) | (22.3) | (29.0) | (20.0) | (13.7) | (7.6) | (15.2) | 2.4 | (18.8) | (12.9) | (6.2) | (8.9) | (2.1) | (1.1) |
| Per Share | ||||||||||||||||
| Basic EPS | (2.23) | (2.26) | (1.15) | (0.83) | (1.18) | (0.87) | (0.88) | — | — | 0.10 | — | — | — | — | — | — |
| Diluted EPS | (2.23) | (2.26) | (1.15) | (0.83) | (1.18) | (0.87) | (0.88) | — | (0.52) | 0.09 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 57.9 | 46.5 | 35.2 | 26.8 | 24.6 | 23.1 | 15.6 | 3.7 | 2.9 | 23.2 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 57.9 | 46.5 | 35.2 | 26.8 | 24.6 | 23.1 | 15.6 | 3.7 | 2.9 | 26.8 | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (106.3) | (41.1) | (23.0) | (29.2) | (20.7) | (13.5) | (7.6) | (15.2) | (12.7) | (16.9) | (12.5) | (6.0) | (6.9) | (2.1) | (4.9) |
| EBIT | (135.2) | (108.1) | (42.6) | (24.1) | (29.7) | (20.9) | (13.7) | (7.7) | (15.3) | (12.9) | (17.0) | (12.6) | (6.0) | (6.9) | (2.1) | (4.9) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.